Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856768 | 0.74 | CA12 (0.41) | HTR3AOPRL1HTR1AHTR2CHTR2A | |
| SCHEMBL3975448 | 0.62 | HTR3A (0.36) | HTR3APTPN1 | |
| SCHEMBL9278725 | 0.61 | CA12 (0.37) | HTR3AOPRL1CA12CA1CA2 | |
| SCHEMBL904865 | 0.59 | BRD4 (0.49) | BRD4CREBBPOPRL1KDM4ERECQL | |
| SCHEMBL10353383 | 0.59 | BRD4 (0.46) | BRD4CREBBPOPRL1 | |
| SCHEMBL762701 | 0.58 | MAOA (0.50) | — | |
| SCHEMBL19844796 | 0.58 | MAOA (0.50) | — | |
| SCHEMBL2603740 | 0.57 | KDM4E (0.47) | BRD4CREBBPOPRL1KDM4ERECQL | |
| SCHEMBL3286493 | 0.57 | MEN1 (0.41) | BRD4CREBBPOPRL1PTPN1 | |
| SCHEMBL8316786 | 0.56 | PSEN1 (0.43) | BRD4CREBBPOPRL1KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | BRD4 1324/4885CREBBP 2019/4885HTR3A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.